Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials | CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic
Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
August 23, 2022
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials | CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus gasseri BGP345A
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : BioFortis
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
Details : Lactobacillus gasseri BGP345A is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Induced Constipation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Lactobacillus gasseri BGP345A
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : BioFortis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGP-014
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
Details : BGP-014 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 12, 2021
Lead Product(s) : BGP-014
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Probiotics on Testosterone in Men
Details : Lactobacillus Reuteri is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable